The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Cantor Fitzgerald reinstated coverage of Pliant Therapeutics (PLRX) with a Neutral rating and no price target The company is discontinuing the ...

Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Fintel reports that on March 4, 2025, Needham downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy to ...

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

Up to 60 new life sciences companies are set to benefit from 1.2 billion euros ($1.27 billion) that Sofinnova Partners has ...

After leaving the Big Breakfast in 1998, Denise decided to pursue a career in acting. She played Roxie Hart in the musical ...

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...

Balance Sheet: At December 31, 2024, Cumberland had $76 million in total assets, including $18 million in cash and cash equivalents. Liabilities totaled $53 million, including $15 million on the ...

Deborah Pound had been married for 40 years before her husband, Shawn, passed away. In 2010, he was diagnosed with ...